In Phase III trials patients with metastatic breast cancer who received WBR plus RSR13 achieved longer survival. RSR13 works by sensitizing oxygen-deprived tumor tissues to enhance the effectiveness of standard radiation therapy and chemotherapy.
|
All times are GMT -7. The time now is 08:59 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021